Mobile Phone Messaging to Support Smoking Cessation Among Office-based Buprenorphine and Inpatient Detoxification Patients: a Pilot Study
Overview
- Phase
- Not Applicable
- Intervention
- Treatment As Usual (TAU)
- Conditions
- Smoking Cessation
- Sponsor
- NYU Langone Health
- Enrollment
- 203
- Locations
- 1
- Primary Endpoint
- Clinical impact assessed using self-reported abstinence at week 1 via a text message inquiry from study
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The primary purpose of this study is to understand the feasibility of a text messaging intervention developed by the National Cancer Institute, known as Smokefreetxt, to improve smoking cessation among opiate and/or alcohol dependent participants discharged from an inpatient detoxification unit and enrolled in an office-based buprenorphine program patients (OBBP). Participants will be randomized to 1) treatment as usual (TAU) comprised of informational pamphlets and information for a 1800 quit line; and a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg) #10, for 28 days which is offered routinely to all inpatients at Bellevue at the time of discharge) versus the SmokeFreeTXT intervention plus prescriptions for NRT.
Investigators
Eligibility Criteria
Inclusion Criteria
- •self-described every or some day smoker
- •diagnosed with opiate dependence and/or alcohol dependence (DSM-IV) per Physician medical records (MISYS)
- •Fluency in English and able to provide a written informed consent
- •Currently owning a mobile phone with a working phone number
- •Expected to reside in the New York City area for the next 12 months
- •Understands and able to respond to the intervention text message
Exclusion Criteria
- •inability to read or understand English
- •currently using nicotine replacement therapies (patch, gum, e-cigarettes), pharmacotherapy for smoking cessation such as bupropion (zyban, wellbutrin), varenicline (Chantix).
- •suicidal or homicidal ideations
- •any ongoing psychotic disorder, life-threatening medical or psychiatric condition
- •leaves the inpatient detoxification unit prior to completing study enrollment
- •is pregnant, nursing or planning to conceive within the duration of the study period
Arms & Interventions
Treatment As Usual (TAU)
Participants will receive informational pamphlets and information for a 1800 quit line, and a prescription for a nicotine replacement therapy (NRT) for 7 Days
Intervention: Treatment As Usual (TAU)
Nicotine Replacement Therapies
Participants will receive a prescription for a nicotine replacement therapy (NRT) for 7 Days.
Intervention: Nicotine Replacement Therapies
Text Message Intervention
Participants will receive up to 5 messages a day with message content informed by principles of cognitive behavioral therapy using software developed and maintained by the National Cancer Institute.
Intervention: Text Message Intervention (TMI)
Outcomes
Primary Outcomes
Clinical impact assessed using self-reported abstinence at week 1 via a text message inquiry from study
Time Frame: 24 Weeks
Difference in patient acceptability assessed via rates of participant adoption of TMI
Time Frame: 24 Weeks
Feasibility measured by rates of retention in the TMI
Time Frame: 24 Weeks
Secondary Outcomes
- Change in pattern of mobile device, computer, and internet usage.(24 Weeks)